Advertisement

Topics

CD22 CAR T-cell immunotherapy trial open for children and young adults whose leukemia escapes CD19 CAR T-cell therapy

06:54 EDT 27 Jul 2017 | Science Daily

After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent. Researchers have now opened a phase 1 clinical trial, PLAT-04, for children and young adults with relapsed or refractory CD22-positive ALL.

Original Article: CD22 CAR T-cell immunotherapy trial open for children and young adults whose leukemia escapes CD19 CAR T-cell therapy

NEXT ARTICLE

More From BioPortfolio on "CD22 CAR T-cell immunotherapy trial open for children and young adults whose leukemia escapes CD19 CAR T-cell therapy"

Quick Search
Advertisement
 

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...